Very nice list, lots of work. Should we add long term cancer recurrence, see below link, tied to ccr5 or too early?

When I get time, I will track some articles down for each MOA you list, many are on the website. Once I have the article tracked I will send a tweet. We could get some people interested in ccr5 coming to look at the research.

The cytodyn website lists MOAs:

https://www.cytodyn.com/pipeline/cance4

Quote:

---

Key Properties of CCR5

Research showed three key properties of the CCR5’s Mechanism of Action (MOA) in cancer. The first is that the CCR5 receptor on cancer cells was responsible for the migration and invasion of cells into the bloodstream, which leads to metastasis of breast, prostate, and colon cancer. Research also discovered that > 50% of 2,200 patients had increased CCR5 expression in their breast cancer. Increased CCR5 expression is an indicator of disease status in several cancers. The second is that blocking the CCR5 receptor also turns on anti-tumor fighting properties restoring immune function. The third key finding was that blockage of the CCR5/CCL5 interaction had a synergistic effect with chemotherapeutic therapy and controlled cancer progression. Chemotherapy traditionally increased expression of CCR5 so blocking it is expected to reduce the levels of invasion and metastasis.
]

---

https://elifesciences.org/articles/43653

Showing a ccr5 long term issue in node-negative, not spread to lymph nodes, cancer (around 5 years) (from a Pestell paper)